100 mg/ml
Sponsors
Karolinska University Hospital, Asso De Recherche Cancers Gynecologiques, Oulu University Hospital, Grifols Therapeutics LLC
Conditions
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)LymphomaMultiple MyelomaPatients with a confirmed diagnosis of ovarian small cell carcinoma.Primaari aivolymfomaaSecondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemiaensilinjan hoito tai hoito relapoituneessa tai refraktaarissa taudissaor Non-Hodgkin Lymphoma
Phase 2
Hyper-CVAD/MA for high-risk aggressive B-cell lymphomas: a single-centre academic phase II trial (HYPERION)
RecruitingCTIS2023-505990-34-00
Start: 2024-11-08Target: 183Updated: 2024-07-08
Multicentric non-randomized phase II of pembrolizumab in combination with etoposide-cisplatin-based chemotherapy in first-line small cell ovarian carcinoma of hypercalcemic type
RecruitingCTIS2024-515310-40-01
Start: 2021-08-04Target: 27Updated: 2026-01-22
Chemoimmunotherapy in conjunction with blood-brain-barrier opening in patients with newly diagnosed or relapsed primary central nervous system lymphoma
Not yet recruitingCTIS2024-519046-79-00
Target: 100Updated: 2024-12-20
Phase 3
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Xembify versus Gamunex-C in Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Not yet recruitingCTIS2025-522165-30-00
Target: 6Updated: 2026-07-07
An Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex®-C plus Standard Medical Treatment to Prevent Infections in Participants with Secondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma (Sigma).
Not yet recruitingCTIS2026-526803-31-00
Target: 31Updated: 2026-09-15